Genmab — Januar 2020

[JKY_VH]

Mcj, tror du har lavet en John Faxe 26.6.92, tlk med det:-)

[Mcjean]

Ja den er pænt ramt, men set i et økonomiske perspektiv kan det vidst ikke sammenlignes:-)

[JKY_VH]

enig

[Riis7]

er 1412 nu os bunden;-)

[NWulff]

E L, not really sure why reduced infusion time should be relevant in a Review focusing on Daratumumab in untreated NDMM patients?

[E_L]

it is relevant for the subcutaneous formulation. We all want SC for the shorter infusion /treatment time ; they point at the importance of the decrease of infusion reactions with SC

[JKY_VH]

Det ved ingen Riis7, men købere i det prisleje har da haft mulighed for at realisere en gevinst.

[Bulder]

Particularly for ND pts convenience is important. The more sick you get, the less important.

[bibob]

Ja, det gik jo nogenlunde i dag.

[lahn1]

Virkelig Bulder - troede det var lige omvendt

[Plimsoller]

God morgen

[bibob]

God morgen.

[transalp]

Go morgen..

[Helge_LarsenPI-redaktør]

God morgen.

[E_L]

Canada CADTH has issued an initial Reimbursement recommendation for #Daratumumab combination (DRd) https://twitter.com/CADTH_ACMTS/status/1214683188615942144 https://cadth.ca/daratumumab-darzalex-multiple-myeloma?utm_source=CONS+List&utm_campaign=487fd1698e-pCODR-08-01-2019-Keytruda-int-pt_COPY_01&utm_medium=email&utm_term=0_f3b3313866-487fd1698e-263130189

[NWulff]

Still why is it relevant in a Review? It is relevant to the patient, in marketing and otherwise in accessing toxicity. Thus time is not of essence in a Review like that. The original literature likely have commented on the matter. If I were ask to peer-review this review I would have had it removed by the authors if they started talking about convenience for patients
.

[Bulder]

yes, you are right

[Plimsoller]

Så er det vist ved at være oppe over hvis meldingen om de 3mia skal komme!

[Legolas23]

Hvorfor?

[gentogen]

Fordi den i princippet tilsvarende kom 8. januar i 2019